SAN DIEGO, CA--(Marketwire - 01/26/10) - SpectraScience, Inc. (OTC.BB:SCIE - News), a San Diego based medical device company, announced today that Jim Hitchin, CEO, was interviewed on blogtalkradio's the "Powerful Patient," where he spoke to the host and audience about SpectraScience's optical biopsy cancer screening technologies which are FDA approved for early detection of colon and cervical cancer. SpectraScience is currently running tests for the early detection of esophageal cancer.

Hitchin said, "The advantage of the Company's technology is that it can screen in real-time and the physician gets a definitive identification of abnormal and/or precancerous tissue immediately as opposed to relying solely on the subjective diagnosis and interpretation by a physician. Currently diagnosis is subject to human error, requires significant time, and is unnecessarily expensive. By using a WavSTAT Optical Biopsy System, a doctor essentially has an unbiased, accurate, low cost pathologist in residence."

When asked about possible future applications for cancer screening, Hitchin said, "Esophageal cancer is next, and the company has plans to develop applications for Inflammatory Bowel Syndrome (IBD) and lung cancer as well."

SpectraScience launched its WavSTAT optical biopsy product in Europe in 2009 and intends to introduce it to the U.S. marketplace this year. The interview can be listened to in its entirety athttp://www.blogtalkradio.com/powerful-patient under the heading "Helping doctors find the right diagnosis."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT Optical Biopsy System and LUMA Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, it's most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.